Austin Psychedelic Medicine Welcome Event
Psychedelic drugs are moving toward medical approval, but their clinical use to date has mostly been limited to research settings. One goal of the McGill Center for Psychedelic Research and Therapy is to build a network of mental health providers in Austin who share an interest in this field so that these unique interventions can be better understood and successfully integrated into psychiatric care.
This will be the inaugural event of Austin Psychedelic Medicine, an interest group hosted by the McGill Center for Psychedelic Research and Therapy. We welcome mental health providers from the area to engage with other clinicians interested in the field and learn from UT Austin faculty actively conducting research on psychedelic treatments.
If you plan to attend please RSVP as soon as possible, as capacity at the venue is limited. If you cannot attend, please include your contact information so that we can send invitations for future events.
Evening Schedule:
5:30-6:45PM – Dinner, drinks, and discussion
6:45PM-7:10PM – Psychedelics and Psychological Change
- David Bender, M.D
7:10PM-7:35PM – Psychedelic Medicine: Current Status and Future Directions
- Greg Fonzo, Ph.D.
7:35-8:00PM- Q&A: The Future for Psychedelic Medicine
- Greg Fonzo Ph.D, David Bender M.D., Manoj Doss Ph. D., Julie Farrington, M.D.
8:30PM - Event closing
Speakers
Dr. David Bender is a psychiatrist and clinical psychedelic researcher at the UT-Austin McGill Center for Psychedelic Research and Therapy. He is an active co-investigator and treatment session facilitator on clinical trials of LSD and psilocybin for mental health conditions. He developed a clinical trial of co-administered LSD and MDMA for the treatment of major depression which will begin enrolling at the Center later this year. His work focuses on characterizing approaches to psychological support used in psychedelic treatments and he has also collaborated on neuroimaging studies of the psychedelic state.
Dr. Manoj Doss is a cognitive neuropsychopharmacologist at The UT Austin Dell Medical School McGill Center for Psychedelic Research and Therapy. His work largely focuses on basic neurocognitive mechanisms of psychedelic drug action to discover how psychedelic therapy can be optimized with cognitive-behavioral manipulations. He is running studies in healthy participants testing the acute effects of psychedelics on memory, cognition, and brain function.
Dr. Greg Fonzo, PhD is an Assistant Professor and Co-Founder/Co-Director of the McGill Center for Psychedelic Research and Therapy, His interest in psychedelics spans several decades, and he is principal investigator on 4 separate psychedelic studies spanning compounds such as ibogaine, psilocybin, and ayahuasca and incorporates non-invasive brain stimulation into psychedelic treatment protocols. His vision is to develop safe, effective, and scalable psychedelic treatment protocols that will transform the landscape of mental health care both locally and globally.
Dr. Julie Farrington is a psychiatrist and the director of clinical trials at the UT-Austin Dell Medical School Department of Psychiatry. She oversees industry sponsored trials and research that includes psychedelics, non-psychedelic investigational products and neuromodulation treatments. Her responsibilities include prioritizing participants' well-being with continuity of care and provider relationships.